INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2024

Investments, All Other Investments [Abstract]

Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):

	March 31, 2024
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash and cash equivalents, excluding money market accounts	$	92,291	$	—	$	—	$	92,291	$	92,291	$	—
Level 1:
Money market accounts	5,180		—		—		5,180		5,180		—
Government & agency securities	15,454		(14)		64		15,504		—		15,504
Equity securities	10,000		2,587		—		12,587		—		12,587
	30,634		2,573		64		33,271		5,180		28,091
Level 2:
Corporate bonds	30,412		182		272		30,866		—		30,866
Total	$	153,337	$	2,755	$	336	$	156,428	$	97,471	$	58,957

	December 31, 2023
	Cost		Unrealized Gains		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash and cash equivalents, excluding money market accounts	$	88,778	$	—	$	—	$	88,778	$	88,778	$	—
Level 1:
Money market accounts	5,662		—		—		5,662		5,662		—
Government & agency securities	15,282		126		40		15,448		—		15,448
Equity securities	10,000		150		—		10,150		—		10,150
	30,944		276		40		31,260		5,662		25,598
Level 2:
Corporate bonds	29,440		293		270		30,003		—		30,003
Total	$	149,162	$	569	$	310	$	150,041	$	94,440	$	55,601

Schedule of Investment Gains

The gains related to the Company’s LifeMD investment for the three months ended March 31, 2024 and 2023 are summarized in the table below (in thousands):

	March 31, 2024		March 31, 2023
Net gains recognized during the period on equity securities	$	2,437	$	—
Less: Net gains recognized on equity securities sold	—		—
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date	$	2,437	$	—